World-leading Breast Cancer Oncologists Cynthia Ma MD, PhD and Massimo Cristofanilli, MD to Join Olaris Scientific and Medical Advisory Board
Share Article
Drs. Cynthia Ma and Massimo Cristofanilli to Advise on Biomarkers of Response (BoRs) to Drive Better Treatment Outcomes for Patients with Breast Cancer
I am impressed by Olaris’s technology and early data suggesting the potential use of a metabolomics signature as an independent and robust predictive biomarker in metastatic breast cancer. - Dr. Cristofanilli WALTHAM, Mass. (PRWEB) February 16, 2021 Olaris, Inc, a precision medicine company leveraging metabolomics and machine learning for the discovery and development of Biomarkers of Response (BoRs) to optimize treatments and patient outcomes, has appointed Dr. Cynthia Ma of Washington University in St. Louis and Dr. Massimo Cristofanilli from Northwestern Medicine to its Scientific Advisory Board and Medic
Nebraska
United-states
Stan-lapidus
Monty-kothiwale
Heliocos-biosciences
Gerhard-wagner
Massimo-cristofanilli
Cynthia-ma
Polaris-inc
Nuclear-magnetic-resonance
Molecular-pharmacology-at-harvard-medical-school
University-of-nebraska